C&G Editor in Chief, Erin Harris
-
Nurix Tx, CBM On Scaling Auto & Allo Therapies
8/11/2022
Cell & Gene Live events cover some of the timeliest topics facing the CGT sector. Our most recent Cell & Gene Live, Scaling Cell Therapies: Auto Vs. Allo, is one such event. This Cell & Gene Live’s focus centered on the need to develop processes that scalable and suitable for a manufacturing environment to scale auto and allo therapies. Michael Blackton, SVP Cell Therapy Manufacturing at Nurix Therapeutics and John Lee, VP Head of Cell Therapy at Center for Breakthrough Medicines shared their expertise from the biopharma and CDMO points of view, respectively.
-
Talaris’ Cell Therapy for Organ Rejection
8/1/2022
Inside the allogeneic stem cell therapies developed to potentially treat rare autoimmune diseases.
-
Glimmers Of Hope For Solid Tumors
7/28/2022
On a recent episode of Cell & Gene: The Podcast, Dr. Carl June and I discussed the future of solid tumors.
-
Omega Therapeutics’ Approach To Epigenetics
7/25/2022
Omega Therapeutics received IND clearance from the FDA to begin trials evaluating its precision approach to epigenetics.
-
TC BioPharm’s In-House Clinical Trials
7/13/2022
Of the topics TC BioPharm’s CEO Bryan Kobel and I discussed on Cell & Gene: The Podcast, it’s the publicly-traded, clinical stage cell therapy biotech’s commitment to U.K.-based in-house clinical trials that struck me most. Indeed, TC BioPharm conducts and manages its own clinical trials using its in-house team. The company boasts a progressive approach to clinical trials, which enables the ability to explore the therapeutic potential of its co-stim CAR product candidate, while working towards an effective treatment for patients in de-risked early studies.
-
UniQure’s AAV Gene Therapy Trial for Huntington’s Disease
6/29/2022
uniQure is a gene therapy company advancing therapies for patients with severe medical needs. The company recently announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease. This is the first-ever AAV gene therapy trial for Huntington’s disease.
-
Does Your Company Need A Site Operations Lead?
6/28/2022
Episode 25 of Cell & Gene: The Podcast features my conversation with Immatics’ Director, Clinical Operations and member of Cell & Gene’s Editorial Advisory Board member, Michael Mehler.
-
Novartis’ T-Charge Platform Spotlights Auto CAR-Ts
6/23/2022
You don’t have search long and hard for news in the CGT sector about companies concentrating on developing and manufacturing allogeneic, or off-the-shelf- therapies. Take Poseida Therapeutics for example. The broad platform technology company boasts auto and allo CAR T-cell therapies for oncology and beyond as well as in vivo and ex vivo gene therapies. In Episode 26 of Cell & Gene: The Podcast, Poseida Therapeutics’ CEO, Mark Gergen, and I talked about the clinical-stage biopharma’s plan to develop allogeneic versions of all of its hematological and solid tumor product candidates.
-
Precision Biosciences’ Race To Allo CAR-T Therapy Approval
6/8/2022
Back in 2020, Precision Biosciences’ Brent Rice, PhD, Director, Manufacturing Science and Technology and Damien Hallet Senior Director, CMC Operations and Strategic Planning wrote an article for Cell & Gene about how successful manufacture of allogeneic CAR T therapies depends on a gene editing technology that maintains the integrity of the T cells and ensures routine, reliable, and consistent production of CAR T batches with the goal of generating 100 doses or more from a single leukopak.
-
Rocket Pharma’s Phase 2 For RP-L201
5/31/2022
Rocket Pharma’s new positive long-term data from its Phase 1/2 trial of lentiviral-based gene therapy RP-L201 for the treatment of Leukocyte Adhesion Deficiency-I (LAD-I). RP-L201 is being developed for LAD-I, a rare genetic immune disorder that predisposes patients to recurrent and fatal infections, often resulting in death within the first two years of life.